AU2006277879A1 - Microparticle compositions of the topoisomerase I inhibitor 7-tert-butoxyiminomethylcamptothecin - Google Patents

Microparticle compositions of the topoisomerase I inhibitor 7-tert-butoxyiminomethylcamptothecin Download PDF

Info

Publication number
AU2006277879A1
AU2006277879A1 AU2006277879A AU2006277879A AU2006277879A1 AU 2006277879 A1 AU2006277879 A1 AU 2006277879A1 AU 2006277879 A AU2006277879 A AU 2006277879A AU 2006277879 A AU2006277879 A AU 2006277879A AU 2006277879 A1 AU2006277879 A1 AU 2006277879A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
cancer
oil
fatty acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006277879A
Other languages
English (en)
Inventor
Oskar Kalb
Isabel Ottinger
Walter Stebler
Agnes Taillardat
Wolfgang Wirth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006277879(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2006277879A1 publication Critical patent/AU2006277879A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006277879A 2005-08-10 2006-08-08 Microparticle compositions of the topoisomerase I inhibitor 7-tert-butoxyiminomethylcamptothecin Abandoned AU2006277879A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10
US60/707,139 2005-08-10
PCT/EP2006/065160 WO2007017514A1 (en) 2005-08-10 2006-08-08 Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin

Publications (1)

Publication Number Publication Date
AU2006277879A1 true AU2006277879A1 (en) 2007-02-15

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006277879A Abandoned AU2006277879A1 (en) 2005-08-10 2006-08-08 Microparticle compositions of the topoisomerase I inhibitor 7-tert-butoxyiminomethylcamptothecin

Country Status (20)

Country Link
EP (1) EP1915132A1 (ja)
JP (1) JP2009504616A (ja)
KR (1) KR20080034989A (ja)
CN (1) CN101287448A (ja)
AR (1) AR055602A1 (ja)
AU (1) AU2006277879A1 (ja)
BR (1) BRPI0614757A2 (ja)
CA (1) CA2618084A1 (ja)
EC (1) ECSP088166A (ja)
GT (1) GT200600364A (ja)
IL (1) IL189076A0 (ja)
MA (1) MA29735B1 (ja)
MX (1) MX2008001965A (ja)
NO (1) NO20081213L (ja)
PE (1) PE20070232A1 (ja)
RU (1) RU2008108885A (ja)
TN (1) TNSN08062A1 (ja)
TW (1) TW200800195A (ja)
WO (1) WO2007017514A1 (ja)
ZA (1) ZA200800726B (ja)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
PE20070232A1 (es) 2007-04-09
JP2009504616A (ja) 2009-02-05
EP1915132A1 (en) 2008-04-30
TNSN08062A1 (en) 2009-07-14
AR055602A1 (es) 2007-08-29
KR20080034989A (ko) 2008-04-22
MX2008001965A (es) 2008-03-26
MA29735B1 (fr) 2008-09-01
CA2618084A1 (en) 2007-02-15
ZA200800726B (en) 2009-08-26
TW200800195A (en) 2008-01-01
WO2007017514A1 (en) 2007-02-15
IL189076A0 (en) 2008-08-07
CN101287448A (zh) 2008-10-15
BRPI0614757A2 (pt) 2011-04-12
NO20081213L (no) 2008-05-13
ECSP088166A (es) 2008-03-26
GT200600364A (es) 2007-03-19
RU2008108885A (ru) 2009-09-20

Similar Documents

Publication Publication Date Title
CA2362277C (en) Spontaneously dispersible n-benzoyl staurosporine compositions
EP1814520B1 (en) Pharmaceutical compositions comprising a camtothecin derivate
US20080279940A1 (en) Microemulsions of Cannabinoid Receptor Binding Compounds
KR101928589B1 (ko) 알리스포리비르를 포함하는 제약 조성물
EP1715848B1 (en) Microemulsion formulations comprising particular substance p antagonists
AU2006277879A1 (en) Microparticle compositions of the topoisomerase I inhibitor 7-tert-butoxyiminomethylcamptothecin
US20100068265A1 (en) Gelatin capsules comprising an acid
KR20070018003A (ko) 특정 물질 ｐ 길항제를 포함하는 마이크로에멀젼 제제

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted